Noopept, Semax and Selank are often grouped together in discussions of cognition, but grouping is not evidence that they produce comparable effects. Their chemical identities, proposed mechanisms and study designs need separate examination before a meaningful comparison is possible.

PubMed indexes a comparative clinical report of Noopept and piracetam in people with cognitive impairment associated with vascular or traumatic brain disease. The indexed record alone is not sufficient to verify every methodological detail or justify a ranking against Semax or Selank. Comparative Noopept and piracetam study indexed in PubMed

A separate human experiment investigated resting-state functional connectivity after Selank or Semax in healthy participants. Neuroimaging changes can be useful mechanistic observations. They do not automatically establish improved memory, reduced anxiety or better day-to-day functioning. Selank and Semax functional connectivity experiment

Avoid comparing unlike endpoints

A clinical symptom scale in patients and a brain-connectivity measurement in healthy volunteers answer different questions. Even statistically significant changes cannot be combined into a single “best nootropic” score without a defensible method.

A stronger comparison would require clearly characterized products, similar populations, meaningful outcomes and adequate control of expectations and repeated testing. It would also need to account for adverse effects and uncertainty rather than treating the absence of reported harm as proof of safety.

Regulatory language needs precision

Research publications do not establish approval. The October 30, 2026 Federal Register notice describes a draft, nonbinding HHS policy on conditional enforcement discretion for peptide compounding under section 503A. The notice also describes interim enforcement discretion while the bulks list is developed; calling the policy draft does not mean it has no interim effect. Its conditions and product scope require separate review. It neither grants FDA approval nor establishes cognitive efficacy. Federal Register peptide policy notice October 30 2026

AXON's conclusion is that the cited evidence cannot support a clinical winner among these compounds. Full-text review, jurisdiction-specific checks and specialist assessment are required before making therapeutic claims. This article supplies no use protocol or combination advice.